Skip to content

Predicting treatment success in anxiety disorder patients by use of biomarkers

Predicting treatment success in anxiety disorder patients by use of biomarkers - Predictive biomarkers for treatment of anxiety

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON46417
Enrollment
75
Registered
2018-07-12
Start date
2019-04-05
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: diagnose of anxiety disorder enrollment at intensive exposure therapy program at Pro Persona/Onderwaal Nijmegen cognitive competent, 18-65 years fMRI compatibility

Exclusion criteria

Exclusion criteria: History of or current or previous neurological disorders, psychosis or delusional disorders History of current brain surgery or epilepsy Pregnancy Metal parts in the upper body, implants, medical devices or medicinal plasters Claustrophobia

Design outcomes

Primary

MeasureTime frame
In the fMR session three paradigms will be tested to determine the neural phenotype: ­ prefrontal regulation task ­ salience processing task ­ face processing task Therapy evaluation: A therapy evaluation is routinly in place at pro Persona including a questionnaire battery. We will analyze the aquestionnaire data regarding the therapy outcome and relate results to previously determined neural mechanisms in the individual patient.

Secondary

MeasureTime frame
questionnaires: ­ FEEL­E (Emotional Adjustment Questionnaire for Adults, Grob & Horowitz, 2014) Biological markers for stress: ­ heart rate ­ skin conductance pupil dilation shoulder muscle tension (MEG)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)